<div id="readability-page-1">Biotech stock Celcuity Inc (NASDAQ:CELC) is skyrocketing today, up 221% at $43.76 at last glance, after upbeat phase 3 trial results for its advanced breast cancer therapy, gedatolisib, which it hopes will have Food &amp; Drug Administration (FDA) approval by the end of the year. The treatment demonstrated a favorable safety profile in comparison to similar drugs, and the triple combo of gedatolisib, Pfizer's (PFE) Ibrance, and AstraZeneca's (AZN) endocrine therapy Faslode reduced the risk of disease progression or death by 76%. Headed for its best day ever, CELC is trading at record highs after blowing past its previous June 25, 2021 all-time peak of $33.01. The equity is also breaking into positive territory year-over-year. Celcuity is seeing much more options activity than usual, though puts are outweighing calls nine to one as traders appear to bet on a correction. The most popular contract today is the August 25 put, with new positions being bought to open there. Analysts have yet to chime in, though all eight in coverage already carry a &#34;buy&#34; or &#34;strong buy&#34; rating. The 12-month consensus price target of $32 is now a discount to current levels, however, so bull notes could keep the wind at the equity's back. </div>

CELC

生物科技股票 Celcuity Inc（納斯達克代碼：CELC）在其乳腺癌療法 gedatolisib 的第三階段臨牀試驗結果積極後，股價飆升 221%，達到 43.76 美元。該治療顯示出 76% 的疾病進展風險降低。CELC 的交易價格創下歷史新高，超過之前的峯值 33.01 美元。儘管期權活動增加，但看跌期權的交易量以九比一的比例超過看漲期權，表明可能存在修正的押注。分析師維持 “買入” 或 “強力買入” 的評級，但 12 個月的目標價 32 美元現已低於當前水平

生物科技股票在晚期試驗結果公佈後迅速上漲